CL04183
Metastatic Colorectal Cancer (mCRC), Triple-Negative Breast Cancer (TNBC), solid tumors, hematological malignancies
Pre-clinicalLead Development Candidate
Key Facts
Indication
Metastatic Colorectal Cancer (mCRC), Triple-Negative Breast Cancer (TNBC), solid tumors, hematological malignancies
Phase
Pre-clinical
Status
Lead Development Candidate
Company
About Cleara Biotech
Cleara Biotech is advancing a novel therapeutic paradigm by targeting distinct subtypes of senescent cells, which are drivers of chronic diseases and cancer progression. Its core technology is a FOXO4/p53-based D-amino acid peptide platform, from which it has optimized two lead candidates, CL04177 and CL04183, targeting 'scarred' senescence. The company, founded on seminal academic research from the University Medical Center Utrecht, is led by a team with deep expertise in senescence biology and clinical development, and is preparing its lead programs for clinical trials in solid tumors and hematological malignancies.
View full company profileTherapeutic Areas
Other Metastatic Colorectal Cancer (mCRC), Triple-Negative Breast Cancer (TNBC), solid tumors, hematological malignancies Drugs
| Drug | Company | Phase |
|---|---|---|
| CL04177 | Cleara Biotech | Pre-clinical |